Northern Star Resources is under Algo Engine buy conditions and remains the only gold stock in our Algo Engine model portfolio.
If inflation is a temporary phenomenon caused by pent-up demand and supply chain issues, it is likely the 10-year yield will run into resistance and gold will soon find renewed buying interest.
Metcash has launched an off-market buyback of up to $175m and increased its dividend payout ratio to 70%.
Metcash is likely to deliver low levels of earnings growth within the 2 – 3% range. The earnings are well supported by improving trends in hardware and liquor. The stock trades on a forward dividend yield of 4.8%.
We highlight that the Algo Engine switched to buy conditions in May at $3.40.
The Fund focuses on Australian and United States large-cap securities and ETFs, to deliver superior risk-adjusted investment returns.
Our unique point of difference is our proprietary algorithm-based investment models, which are designed to quantify market momentum and remove much of the emotional human bias in the investment decision-making process.
Two classes of units in the Fund are offered:-
Class A Units – which provide investment exposure to ASX Listed securities and exchange-traded funds.
Class B Units – which provide investment exposure to United States listed securities and exchange-traded funds.
REA Group is among the best-performing stocks in our ASX 100 model portfolio, with the share price up 57% since being added in September last year.
REA Group has acquired 100 percent of the shares in Mortgage Choice for $1.95 a share, valuing the company at $244 million. REA is now focused on accelerating its financial services strategy to become a leading player in the home loan market.
REA is a high quality business with terrific growth potential, however, the 65x PE multiple is a little rich and we recommend waiting for the next Algo Engine buy signal.
Lendlease has issued a profit warning indicating statutory profit after tax of $200 – $320 million, blaming the interruptions caused by the coronavirus, which have hit rents and development activity in London especially hard.
The group’s balance sheet remains strong with gearing expected to be below the bottom end of the target range of 10-20%.
The current weakness in the Crown share price could be a buying opportunity. It’s unlikely that the current COVID-related operational impacts are going to deter the interested parties who have put forward takeover offers.
CURE:AXW is under Algo Engine buy conditions and the current pullback provides another buying opportunity.
ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. biotechnology companies. These companies are engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.